WilmerHale Represents ZebiAI Therapeutics in Acquisition by Relay Therapeutics

WilmerHale Represents ZebiAI Therapeutics in Acquisition by Relay Therapeutics

Client News

Related Solutions

Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

On April 16, 2021, ZebiAI Therapeutics, Inc., an artificial intelligence company that pioneers the application of machine learning to massive datasets to enable drug discovery, and Relay Therapeutics, Inc. (Nasdaq: RLAY) announced that they have entered into a definitive merger agreement pursuant to which Relay would acquire ZebiAI for $85 million of upfront payments, composed of $20 million in cash and $65 million in Relay common stock, plus up to an additional $185 million of contingent payments based on the achievement of certain platform- or program-related milestones, payable in Relay common stock, and a percentage of the proceeds of certain agreements entered into by Relay, payable in cash. 

WilmerHale is representing ZebiAI in the deal, with a team led by Chris Barnstable-Brown, Ariel Soiffer and Jenna Ventorino, which also included Samantha Berkovits, Erin Anderson and Elijah Soko on corporate and M&A matters, and Scott Kilgore, Julie Hogan Rodgers and Meghan Walsh on employment, equity compensation and tax matters.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel